Trading Signals: CLVS Stock Price Prediction and Forecast (Wed. Nov. 16, 2011 - Fri. Aug. 6, 2021)(Clovis Oncology Inc. )
| Market is closed on Thu. Sep. 9, 2021 | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 0% (three month average) | | RSI | | | Latest Price | $(0%) | | Stocks Behave Similarly | Similar Stock List | | Market Behavior | Broad based sell-off for large cap. Normal for small cap. | | Correlated ETFs | Broad market will support CLVS advance at 0% a week (0% probability)
(0%) (0%) (0%) (0%) (0%) | | Factors Impacting CLVS price | CLVS will advance at least -0% in a week (0% probabilities).
(0%) (0%) (0%) (0%) (0%) | | | | | | | | Relative Volatility | | | | | | Market Trend Strength | 0% (StdDev 0%) | | Hourly BBV | 0 () | | Intraday Trend | NAN% | | | | | |
|
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. |